EXTON, Pa., Sept. 18, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio and slide webcast of its analyst and investor seminar, focusing on the company's commercial product projections and future growth opportunities on Friday, September 21, 2012. Lectures will be provided by a number of ViroPharma representatives.
The seminar, entitled " Broadening Horizons," will be held from 9:00 A.M. until 12:45 P.M. Eastern Time on Friday, September 21, 2012. Among the topics ViroPharma will discuss are: plans and opportunities for furthering Cinryze ® (C1 esterase inhibitor [human]) growth in North America; updates on launch progress and projections for Cinryze, Buccolam ® (midazolam, oromucosal solution), and Plenadren ® (hydrocortisone, modified release tablet) in the European Union; development pipeline updates including interim data from select clinical studies; and a financial overview, including longer term financial guidance.
"We are excited to be in position to not only provide continued growth with our cornerstone product, Cinryze, here in North America and in Europe, but also to be moving ahead on numerous other commercial products and development opportunities to deliver sustained growth well into the back half of the decade and beyond," commented Vincent Milano, ViroPharma's president and chief executive officer. "We look forward to this event and sharing our plans with the investment community as they can begin to share in our vision of both the short and long term milestones in the path forward for ViroPharma."
A live webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website, http://www.viropharma.com. The archive of the meeting will be available through October 31, 2012.About Cinryze ® (C1 esterase inhibitor [human]) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product. In the U.S., Cinryze is approved by the FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In the E.U., the product is approved by the EMA for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only. Severe hypersensitivity reactions to Cinryze may occur. Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy. Monitor patients with known risk factors for thrombotic events. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV